{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:23:22Z","timestamp":1792041802017,"version":"4.4.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund (FWF)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.leukres.2017.05.008","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T17:01:23Z","timestamp":1494608483000},"page":"47-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML"],"prefix":"10.1016","volume":"59","author":[{"given":"Peter","family":"Valent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"Hadzijusufovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Hoermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"F\u00fcreder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerit-Holger","family":"Schernthaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Kirchmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.leukres.2017.05.008_bib0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.leukres.2017.05.008_bib0010","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.leukres.2017.05.008_bib0015","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2017.05.008_bib0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1535-6108(02)00025-9","article-title":"Perspectives on the development of a molecularly targeted agent","volume":"1","author":"Druker","year":"2002","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1016\/j.leukres.2017.05.008_bib0025","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.leukres.2017.05.008_bib0030","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2017.05.008_bib0035","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.leukres.2017.05.008_bib0040","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2017.05.008_bib0045","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer Control."},{"issue":"4","key":"10.1016\/j.leukres.2017.05.008_bib0050","first-page":"534","article-title":"New tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"90","author":"Martinelli","year":"2005","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2017.05.008_bib0055","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.seminhematol.2010.06.005","article-title":"Resistance to imatinib: mutations and beyond","volume":"47","author":"La Ros\u00e9e","year":"2010","journal-title":"Semin. Hematol."},{"issue":"5S","key":"10.1016\/j.leukres.2017.05.008_bib0060","doi-asserted-by":"crossref","first-page":"663","DOI":"10.6004\/jnccn.2013.0196","article-title":"Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia","volume":"11","author":"Radich","year":"2013","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"5","key":"10.1016\/j.leukres.2017.05.008_bib0065","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clml.2013.03.018","article-title":"Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options","volume":"13","author":"Jabbour","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"5","key":"10.1016\/j.leukres.2017.05.008_bib0070","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2017.05.008_bib0075","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2141.2008.07197.x","article-title":"Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease","volume":"142","author":"Valent","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"21","key":"10.1016\/j.leukres.2017.05.008_bib0080","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","article-title":"Maciejewski JP. CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia","volume":"117","author":"Makishima","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2017.05.008_bib0085","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2017.05.008_bib0090","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2017.05.008_bib0095","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.14694\/EdBook_AM.2015.35.e381","article-title":"Diagnosing and managing advanced chronic myeloid leukemia","author":"Deininger","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"24","key":"10.1016\/j.leukres.2017.05.008_bib0100","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.leukres.2017.05.008_bib0105","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.leukres.2017.05.008_bib0110","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.leukres.2017.05.008_bib0115","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2017.05.008_bib0120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial","volume":"168","author":"Br\u00fcmmendorf","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"22","key":"10.1016\/j.leukres.2017.05.008_bib0125","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.leukres.2017.05.008_bib0130","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.leukres.2017.05.008_bib0135","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.leukres.2017.05.008_bib0140","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1586\/ehm.10.61","article-title":"Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study","volume":"3","author":"Giles","year":"2010","journal-title":"Expert. Rev. Hematol."},{"issue":"28","key":"10.1016\/j.leukres.2017.05.008_bib0145","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2017.05.008_bib0150","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2017.05.008_bib0155","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","article-title":"Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors","volume":"25","author":"Bantscheff","year":"2007","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.leukres.2017.05.008_bib0160","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","article-title":"Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells","volume":"23","author":"Remsing Rix","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2017.05.008_bib0165","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","article-title":"Extended kinase profile and properties of the protein kinase inhibitor nilotinib","volume":"1804","author":"Manley","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"7","key":"10.1016\/j.leukres.2017.05.008_bib0170","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am. J. Hematol."},{"issue":"17","key":"10.1016\/j.leukres.2017.05.008_bib0175","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Le Coutre","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.leukres.2017.05.008_bib0180","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.leukres.2017.05.008_bib0185","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.leukres.2017.05.008_bib0190","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100mg once daily preserves efficacy and improves tolerability in imatinib-resistant and \u2212intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2017.05.008_bib0195","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cncr.24734","article-title":"Dasatinib 100\u2009mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion","volume":"116","author":"Porkka","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2017.05.008_bib0200","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.2010.030494","article-title":"Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100mg or 50mg daily","volume":"96","author":"Krauth","year":"2011","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.leukres.2017.05.008_bib0205","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.leukres.2008.09.026","article-title":"Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia","volume":"33","author":"Rasheed","year":"2009","journal-title":"Leuk. Res."},{"issue":"17","key":"10.1016\/j.leukres.2017.05.008_bib0210","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.leukres.2017.05.008_bib0215","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2169\/internalmedicine.51.7472","article-title":"Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia \u2212 critical alert","volume":"51","author":"Sano","year":"2012","journal-title":"Intern. Med."},{"issue":"6","key":"10.1016\/j.leukres.2017.05.008_bib0220","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3109\/10428194.2015.1091929","article-title":"Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis","volume":"57","author":"Chai-Adisaksopha","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.leukres.2017.05.008_bib0225","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/leu.2015.352","article-title":"Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials","volume":"30","author":"le Coutre","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.leukres.2017.05.008_bib0230","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.3324\/haematol.2013.086355","article-title":"Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia","volume":"98","author":"Racil","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2017.05.008_bib0235","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","article-title":"Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia","volume":"99","author":"Rea","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.leukres.2017.05.008_bib0240","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12185-012-1222-7","article-title":"Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin","volume":"97","author":"Ito","year":"2013","journal-title":"Int. J. Hematol."},{"issue":"21","key":"10.1016\/j.leukres.2017.05.008_bib0245","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.1503.1503","article-title":"Hypercholesterolemia in imatinib intolerant\/resistant CML-CP patients treated with nilotinib: a retrospective analysis","volume":"122","author":"Hiwase","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2017.05.008_bib0250","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","article-title":"Nilotinib-associated vascular events","volume":"12","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"6","key":"10.1016\/j.leukres.2017.05.008_bib0255","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2017.05.008_bib0260","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ejh.12096","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study","volume":"90","author":"Levato","year":"2013","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.leukres.2017.05.008_bib0265","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/ejh.12367","article-title":"Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome","volume":"94","author":"Mirault","year":"2015","journal-title":"Eur. J. Haematol."},{"issue":"19","key":"10.1016\/j.leukres.2017.05.008_bib0270","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.leukres.2017.05.008_bib0275","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/leu.2013.320","article-title":"Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib","volume":"28","author":"Mayer","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2017.05.008_bib0280","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.leukres.2017.05.008_bib0285","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2017.05.008_bib0290","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.leukres.2017.05.008_bib0295","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: eNESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.05.008_bib0300","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1182\/blood.V126.23.4031.4031","article-title":"Assessment of cardiovascular events in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors","volume":"126","author":"Pagnano","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2017.05.008_bib0305","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/M15-2306","article-title":"Swedish CML group and the swedish CML register group: cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study","volume":"165","author":"Dahl\u00e9n","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.leukres.2017.05.008_bib0310","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.V128.22.1919.1919","article-title":"Cardiovascular events among patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs)","volume":"128","author":"Sam","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.008_bib0315","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","author":"Douxfils","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.leukres.2017.05.008_bib0320","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1182\/blood.V120.21.3756.3756","article-title":"Analysis of clinical arterial and metabolic parameters in chronic phase CML patients on nilotinib in a single center cohort","volume":"120","author":"Labussi\u00e8re-Wallet","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.008_bib0325","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1182\/blood.V122.21.1491.1491","article-title":"Real-life comparison of severe vascular events and other non-hematological complications in CML patients treated with second line nilotinib or dasatinib","volume":"122","author":"Gora-Tybor","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.008_bib0330","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1182\/blood.V122.21.4018.4018","article-title":"Peripheral arterial occlusive disease (PAOD) in chronic phase chronic myeloid leukemia patients treated with nilotinib","volume":"122","author":"Jeon","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.008_bib0335","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood.V122.21.257.257","article-title":"Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-iduced vasculopathy in CML","volume":"122","author":"Hadzijusufovic","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.008_bib0340","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1182\/blood.V122.21.2726.2726","volume":"122","author":"Rea","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.008_bib0345","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3324\/haematol.2015.129221","article-title":"Long-term outcome of a phase 2 trial with nilotinib 400mg twice daily in first-line treatment of chronic myeloid leukemia","volume":"100","author":"Gugliotta","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2017.05.008_bib0350","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1182\/blood.V122.21.4012.4012","article-title":"Adverse events (AE) under imatinib treatment over 10 years: results from 1501 patients of the randomized CML-study IV","volume":"122","author":"Hehlmann","year":"2013","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2017.05.008_bib0355","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1200\/JCO.2004.04.217","article-title":"Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment","volume":"22","author":"Breccia","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2017.05.008_bib0360","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/01.ATV.0000124105.39900.db","article-title":"Imatinib attenuates diabetes-associated atherosclerosis","volume":"24","author":"Lassila","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"10","key":"10.1016\/j.leukres.2017.05.008_bib0365","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3324\/haematol.2011.041251","article-title":"Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib","volume":"96","author":"Breccia","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.leukres.2017.05.008_bib0370","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"de Lavallade","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.leukres.2017.05.008_bib0375","first-page":"1395","article-title":"Severe adverse events associated with the use of second-line BCR\/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities","volume":"96","author":"Valent","year":"2011","journal-title":"Haematologica"},{"issue":"26","key":"10.1016\/j.leukres.2017.05.008_bib0380","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.leukres.2017.05.008_bib0385","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1073\/pnas.1312148111","article-title":"JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms","volume":"111","author":"Etheridge","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"44","key":"10.1016\/j.leukres.2017.05.008_bib0390","doi-asserted-by":"crossref","first-page":"72311","DOI":"10.18632\/oncotarget.11100","article-title":"Genetic predisposition and induced pro-inflammatory\/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients","volume":"7","author":"Bocchia","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2017.05.008_bib0395","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood.V124.21.1800.1800","article-title":"Further evaluation of pro-Atherogenic and anti-Angiogenic effects of nilotinib in mice and in patients with Ph-Chromosome+ CML","volume":"124","author":"Hadzijusufovic","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.008_bib0400","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood.V128.22.1883.1883","article-title":"Ponatinib exerts multiple effects on vascular endothelial cells: possible mechanisms and explanations for the adverse vascular events seen in CML patients treated with ponatinib","volume":"128","author":"Hadzijusufovic","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2017.05.008_bib0405","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/10428194.2016.1239258","article-title":"Ponatinib reduces viability, migration, and functionality of human endothelial cells","volume":"58","author":"Gover-Proaktor","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2017.05.008_bib0410","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000023823","article-title":"What have mast cells to do with edema formation, the consecutive repair and fibrinolysis?","volume":"115","author":"Valent","year":"1998","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"2","key":"10.1016\/j.leukres.2017.05.008_bib0415","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4049\/jimmunol.162.2.1032","article-title":"The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis","volume":"162","author":"Sillaber","year":"1999","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.leukres.2017.05.008_bib0420","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1055\/s-0037-1613084","article-title":"New aspects in thrombosis research: possible role of mast cells as profibrinolytic and antithrombotic cells","volume":"87","author":"Valent","year":"2002","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.leukres.2017.05.008_bib0425","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.18632\/oncotarget.3074","article-title":"Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia","volume":"6","author":"Cerny-Reiterer","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.leukres.2017.05.008_bib0430","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12185-012-1222-7","article-title":"Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin","volume":"97","author":"Ito","year":"2013","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2017.05.008_bib0435","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood.V128.22.3098.3098","article-title":"A genetic risk score for insulin resistance identifies patients with chronic myeloid leukemia treated with nilotinib developing diabetes","volume":"128","author":"Martino","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.05.008_bib0440","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutationbased resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.leukres.2017.05.008_bib0445","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.atherosclerosis.2011.01.037","article-title":"Pleiotropic role for monocyte C-fms protein in response to vascular injury: potential therapeutic target","volume":"216","author":"Metharom","year":"2011","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.leukres.2017.05.008_bib0450","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/ki.2013.339","article-title":"Suppressed soluble Fms-like tyrosine kinase-1 production aggravates atherosclerosis in chronic kidney disease","volume":"85","author":"Matsui","year":"2014","journal-title":"Kidney Int."},{"issue":"10","key":"10.1016\/j.leukres.2017.05.008_bib0455","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.1653708","article-title":"Role of platelet-derived growth factors in physiology and medicine","volume":"22","author":"Andrae","year":"2008","journal-title":"Genes Dev."},{"issue":"4","key":"10.1016\/j.leukres.2017.05.008_bib0460","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2362.2009.02095.x","article-title":"PDGF-C and \u2212D and their receptors PDGFR-alpha and PDGFR-beta in atherosclerotic human arteries","volume":"39","author":"Karvinen","year":"2009","journal-title":"Eur. J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.leukres.2017.05.008_bib0465","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009191","article-title":"Insulin receptor signaling in normal and insulin-resistant states","volume":"6","author":"Boucher","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"2","key":"10.1016\/j.leukres.2017.05.008_bib0470","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.tem.2015.11.009","article-title":"Endothelial IGF-1 receptor signalling in diabetes and insulin resistance","volume":"27","author":"Cubbon","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.leukres.2017.05.008_bib0475","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1365-2362.2010.02328.x","article-title":"Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR\/ABL1 kinase inhibitor?","volume":"40","author":"Valent","year":"2010","journal-title":"Eur. J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.leukres.2017.05.008_bib0480","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.25717","article-title":"Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.leukres.2017.05.008_bib0485","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.blre.2014.06.001","article-title":"Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia","volume":"28","author":"Mathisen","year":"2014","journal-title":"Blood Rev."},{"issue":"6","key":"10.1016\/j.leukres.2017.05.008_bib0490","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"11","key":"10.1016\/j.leukres.2017.05.008_bib0495","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2017.05.008_bib0500","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.24362","article-title":"Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia","volume":"91","author":"Gugliotta","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"14","key":"10.1016\/j.leukres.2017.05.008_bib0505","doi-asserted-by":"crossref","first-page":"23061","DOI":"10.18632\/oncotarget.15481","article-title":"TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML","volume":"8","author":"Valent","year":"2017","journal-title":"Oncotarget"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617304228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617304228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T14:55:28Z","timestamp":1692802528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617304228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":101,"alternative-id":["S0145212617304228"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.05.008","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}